http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-045260-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1543b2b19ec0e331a0dcd89888cbef5f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate | 2004-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-045260-A1 |
| titleOfInvention | COMPOUNDS CONTAINING IMIDAZO-OXIMA REPLACED |
| abstract | Pharmaceutical compositions containing the compounds, intermediates, and methods of using these compounds as immunomodulators, to induce cytokine biosynthesis in animals and in the treatment of diseases that include viral and neoplastic diseases. Claim 1: A compound of formula (1), in which: X is selected from the group consisting of -CH (R9a) -alkylene- and -CH (R9a) -alkenylene-, where alkylene and alkenylene are optionally interrupted with one or more groups -O-; R1 and R 'are independently selected from the group consisting of: hydrogen; I rent; alkenyl; aryl; arylalkylenyl; heteroaryl; heteroarylalkylenyl; heterocyclyl; heterocyclylalkylenyl; and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted with one or more substituents selected from the group consisting of: hydroxyl; I rent; haloalkyl; hydroxyalkyl; alkoxy; dialkylamino; -S (O) 0-2-alkyl; -S (O) 0-2-aryl; -NH-S (O) 2-alkyl; -NH-S (O) 2-aryl; haloalkoxy; halogen; nitrile; nitro; aryl; heteroaryl; heterocyclyl; aryloxy; arylalkyleneoxy; -C (O) -O-alkyl; -C (O) -N (R8) 2; -N (R8) -C (O) -alkyl; -O-C (O) -alkyl; and -C (O) -alkyl; or R1 and R 'can be joined together to form a ring system selected from the group consisting of: formula (2), in which the total amount of atom in the ring is 4 to 9, and formula (3), where the total amount of atoms in the ring is 4 to 9; RA and RB are each independently selected from the group consisting of: hydrogen; halogen; I rent; alkenyl; alkoxy; alkylthio; and -N (R9) 2; or when taken together, RA and RB form a heteroaryl ring or a fused aryl ring containing a heteroatom selected from the group consisting of N and S, where the aryl or heteroaryl ring is unsubstituted or is substituted with one or more R groups '' '; or when taken together, RA and RB form a fused saturated 5 to 7 member ring, optionally containing a heteroatom selected from the group consisting of N and S; and is unsubstituted or substituted with one or more R groups; R is selected from the group consisting of: halogen; hydroxyl; I rent; alkenyl; haloalkyl; alkoxy; alkylthio; and -N (R9a) 2; A 'is selected from the group consisting of -O-, -S (O) 0-2-, -N (-Q-R4) -, and -CH2-; Q is selected from the group consisting of a link, -C (R6) -, -C (R6) -C (R6) -, -S (O) 2-, -C (R6) -N (R8) -W -, -S (O) 2-N (R8) -, -C (R6) -O-, and -C (R6) -N (OR9) -; W is selected from the group consisting of a link, -C (O) -, and -S (O) 2-; Rc and Rd are independently selected from the group consisting of hydrogen, halogen, hydroxyl, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N (R9) 2; or Rc and Rd can be joined to form a fused aryl ring or a fused 5-10 membered heteroaryl ring containing one to four heteroatoms; R4 are selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylene, alkylaryl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylene, alkylheteroarylenyl, and heterocyclyl groups, wherein the alkyl, alkenyl, arylalkyl, alkynyl, alkynyl, alkynyl, alkynyl alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylene, alkylheteroarylenyl, and heterocyclyl may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxyl, mercapto, mercapto, mercapto, mercapto, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino) alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; each R6 is independently selected from the group consisting of = O and = S; each R8 is independently selected from the group consisting of hydrogen, C1-10 alkyl, C2-10 alkenyl, (C1-10) alkoxy-(C1-10) alkylene, and aryl (C1-10) alkylene; each R9 is independently selected from the group consisting of hydrogen and alkyl; R9a is selected from the group consisting of hydrogen and alkyl that is optionally interrupted with one or more -O- groups; each R11 is independently C1-6 alkylene or C2-6 alkenylene, where the alkylene or alkenylene is optionally interrupted with a heteroatom; R12 is selected from the group consisting of a bond, C1-5 alkylene and C2-5 alkenylene, where the alkylene or alkenylene is optionally interrupted with a heteroatom; R '' is hydrogen or a non-interfering substituent; and each R '' 'is a non-interfering substituent, or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2003-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 44.